Taysha Gene Therapies, Inc. Labor and Related Expense
Taysha Gene Therapies, Inc. (TSHA) reported Labor and Related Expense of $16.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LaborAndRelatedExpense · last filed 2026-08-11
- Taysha Gene Therapies, Inc. labor and related expense for the quarter ending 2026-06-30 was $16.38M, a 50.94% increase year-over-year.
- Taysha Gene Therapies, Inc. labor and related expense for the quarter ending 2026-03-31 was $15.39M, a 36.56% increase year-over-year.
- Taysha Gene Therapies, Inc. labor and related expense for the quarter ending 2025-12-31 was $14.45M, a 49.50% increase year-over-year.
- Taysha Gene Therapies, Inc. labor and related expense for the quarter ending 2025-09-30 was $11.11M, a 19.69% increase year-over-year.
- Taysha Gene Therapies, Inc. labor and related expense for fiscal 2025 was $47.68M, a 31.09% increase from fiscal 2024.
- Taysha Gene Therapies, Inc. labor and related expense for fiscal 2024 was $36.37M, a 37.21% increase from fiscal 2023.
- Taysha Gene Therapies, Inc. labor and related expense for fiscal 2023 was $26.51M.
| Period end | Labor and Related Expense 3 month | Labor and Related Expense 6 month | Labor and Related Expense 9 month | Labor and Related Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.38M 10-Q · filed 2026-08-11 | $31.77M 10-Q · filed 2026-08-11 | $46.22M derived: sum of 3 quarters · filed 2026-08-11 | $57.33M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $15.39M 10-Q · filed 2026-05-06 | $29.84M derived: sum of 2 quarters · filed 2026-05-06 | $40.95M derived: sum of 3 quarters · filed 2026-05-06 | $51.80M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $14.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $25.56M derived: sum of 2 quarters · filed 2026-03-19 | $36.41M derived: sum of 3 quarters · filed 2026-08-11 | $47.68M 10-K · filed 2026-03-19 |
| 2025-09-30 | $11.11M 10-Q · filed 2025-11-04 | $21.96M derived: sum of 2 quarters · filed 2026-08-11 | $33.23M 10-Q · filed 2025-11-04 | $42.90M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $10.85M 10-Q · filed 2026-08-11 | $22.12M 10-Q · filed 2026-08-11 | $31.79M derived: sum of 3 quarters · filed 2026-08-11 | $41.07M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $11.27M 10-Q · filed 2026-05-06 | $20.93M derived: sum of 2 quarters · filed 2026-05-06 | $30.22M derived: sum of 3 quarters · filed 2026-05-06 | $39.36M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $9.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $18.95M derived: sum of 2 quarters · filed 2026-03-19 | $28.09M derived: sum of 3 quarters · filed 2026-03-19 | $36.37M 10-K · filed 2026-03-19 |
| 2024-09-30 | $9.28M 10-Q · filed 2025-11-04 | $18.43M derived: sum of 2 quarters · filed 2025-11-04 | $26.71M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $9.14M 10-Q · filed 2025-08-12 | $17.42M 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $8.28M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $26.51M 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |